Sun Pharmaceutical Industries gets 10 observations from US FDA for Halol facility

The US FDA conducted a Good Manufacturing Practices (GMP) inspection of Sun Pharmaceutical Industries Limited's Halol facility (Gujarat, India) from April 26 to May 9, 2022. At the conclusion of the inspection, the US FDA issued a Form-483, with 10 observations.

The Company is preparing the response to the observations, which will be submitted to the US FDA within 15 business days. The Company is committed to addressing these observations promptly. The Company remains committed to working closely with the US FDA and continues to enhance its GMP compliance on an ongoing basis.

Shares of Sun Pharmaceutical Industries Limited was last trading in BSE at Rs. 885.35 as compared to the previous close of Rs. 882.60. The total number of shares traded during the day was 118212 in over 2623 trades.

The stock hit an intraday high of Rs. 891.00 and intraday low of 866.00. The net turnover during the day was Rs. 103767734.00.

Source : Equity Bulls

Keywords

SunPharmaceuticalIndustries INE044A01036 USFDA GMP Halol Gujarat India 10Observations Form483